Achmea Investment Management B.V. significantly reduced its position in Regeneron Pharmaceuticals by 90.5% in the fourth ...

The list, which could be expanded over time, will eliminate up to 25% of these reauthorization requirements and accounts for ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a market cycle on a risk-adjusted basis. This ...

Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial. The promising finding, in one ...